{
  "docId": "019de515-1bf5-75fc-a19f-ef7a3323e229",
  "docSlug": "a43786f91ea3b101a0e62521077ddab4",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 14 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 14,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/9",
  "deckHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229",
  "deckJsonHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json",
  "deckAnchorHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.39
      },
      "kind": "diagram",
      "text": "Late Q4 2020: Adintrevimab IND Enabling & Submission; 1H 2021: Phase 1 First in Human 1st Subject Dosed, EVADE (prevention) Ph2/3 Enrollment Initiated (US); 2H 2021: STAMP (treatment) Ph2/3 Enrollment Initiated (ex-US); Q1 2022: Adintrevimab Topline Data",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fde21b91-37af-4a48-8057-9f56f7777bbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.54,
        "y": 0.78
      },
      "kind": "image",
      "text": "STAMP",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b93ce5d-34aa-4968-b866-0a3a798db77c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.37,
        "y": 0.78
      },
      "kind": "image",
      "text": "EVADE",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59f3f9d9-997b-436c-896f-301d9edaa336",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.06,
        "x": 0.89,
        "y": 0.16
      },
      "kind": "image",
      "text": "INVIVYD",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8586967-1007-4cc2-9083-355ba9973a50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.64,
        "x": 0.045,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Adintrevimab is an investigational product candidate that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "309d49dc-80ea-43f1-a29f-80c086298f04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.889,
        "x": 0.045,
        "y": 0.08
      },
      "kind": "title",
      "text": "DEMONSTRATED DEVELOPMENT SUCCESS AND SPEED WITH ADINTREVIMAB: FROM IND TO TOPLINE DATA IN 16 MONTHS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a7c515b-b1c7-4b81-a994-1871ed50a9ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 5,
      "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0",
      "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.",
      "position": 1,
      "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}